|Page (1) of 1 - 06/28/12||email article||print page|
PropThink Interview: Sagent CEO "Actively Pursuing M&A Targets"(June 28, 2012)
NEW YORK, NY -- (Marketwire) -- 06/28/12 -- In an exclusive video interview with PropThink.com, Sagent Pharmaceuticals (NASDAQ: SGNT) President and CEO Jeff Yordon comments on healthcare reform, addressing pricing controls introduced with the Medicare Modernization Act and supply issues that have inevitably followed. The company is countering these pressures by drafting unique contracts with its customers. Says Yordon:
"We are going to absolutely guarantee supply on a bunch of products and in return we want to have a guarantee that we will get a fair price for that. So we're not going to be the highest; we're not going to be the lowest; we're going to make a reasonable margin."
Sagent's Chief Executive is also confident he can better market smaller products than the companies who spend more on overhead than they see in sales by leveraging their network of manufacturers and distributors.
"[Sagent] is very non-traditional; the idea is to try and build a portfolio as quickly as [we] possibly can. And we're doing that through partnerships."
Click here to watch the exclusive interview with Jeffrey M. Yordon, President, Chief Executive Officer and Chairman of the Board of Sagent: http://www.propthink.com/sagent-ceo-were-actively-pursuing-ma-targets-we-can-leverage-with-our-network/
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on our website.
Copyright @ Marketwire
Related Keywords: PropThink, Marketwire,